Cargando…

A Novel Diagnostic Model for Primary Adrenal Lymphoma

OBJECTIVE: Primary adrenal lymphoma (PAL) is easily misdiagnosed as other adrenal masses, such as adrenocortical carcinoma and pheochromocytoma, but patients with PAL benefit little from surgery. The diagnostic method for PAL thus far is limited to adrenal biopsy. In our study, we aimed to develop a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Kai, Xue, Qingping, Zhou, Fangli, Tian, Haoming, Xiang, Qiao, Chen, Tao, Ren, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050348/
https://www.ncbi.nlm.nih.gov/pubmed/33868171
http://dx.doi.org/10.3389/fendo.2021.636658
_version_ 1783679583517671424
author Yu, Kai
Xue, Qingping
Zhou, Fangli
Tian, Haoming
Xiang, Qiao
Chen, Tao
Ren, Yan
author_facet Yu, Kai
Xue, Qingping
Zhou, Fangli
Tian, Haoming
Xiang, Qiao
Chen, Tao
Ren, Yan
author_sort Yu, Kai
collection PubMed
description OBJECTIVE: Primary adrenal lymphoma (PAL) is easily misdiagnosed as other adrenal masses, such as adrenocortical carcinoma and pheochromocytoma, but patients with PAL benefit little from surgery. The diagnostic method for PAL thus far is limited to adrenal biopsy. In our study, we aimed to develop a quick and efficient diagnostic method for PAL. METHODS AND RESULTS: At the same institution, 505 patients (between 2009 and 2019) and 171 patients (between 2019 and 2020) were separately included in the primary and validation studies. Univariate and multivariate analyses were conducted to evaluate clinical manifestations, laboratory findings, and radiological characteristics. Four determinants (age, bilateral masses, high-density lipoprotein cholesterol, and lactate dehydrogenase) were selected and further incorporated into a regression model to screen PAL. Accordingly, the nomogram was developed for clinical practice. In the primary study, the nomogram showed good discrimination, with an area under the receiver operating characteristic (ROC) curve (AUC) of 95.4% (95% CI, 90.6%–100.0%). Further validation study verified the efficacy of the nomogram, with an AUC of 99.0% (95% CI, 96.9%–100.00%) and 100.0% in all patients and patients with bilateral masses, respectively, and a sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV) of 66.67%/99.40%/66.67%/99.40%, 66.67%/100%/100%/92.86%, 50%/99.20%/50%/99.20%, and 100%/100%/100%/100%, in all patients, patients with bilateral adrenal masses, patients with nonfunctional adrenal masses, and patients with positive catecholamine results, respectively. The validation study also revealed a diagnostic specificity of 99.35% and 100% for patients with a unilateral adrenal mass and functional PCC, respectively. CONCLUSIONS: The presented nomogram is the first user-friendly diagnostic model for PAL that simplifies the complex diagnostic process into personalized numeric estimates. We deem that patients who score below 50 are less likely to have PAL. We suggest that clinicians should arrange adrenal biopsy and surgery for patients with nonfunctional tumors and overt catecholamine-secreting tumors, respectively, who receive a score of 50 points or higher to confirm the diagnosis as soon as possible.
format Online
Article
Text
id pubmed-8050348
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80503482021-04-17 A Novel Diagnostic Model for Primary Adrenal Lymphoma Yu, Kai Xue, Qingping Zhou, Fangli Tian, Haoming Xiang, Qiao Chen, Tao Ren, Yan Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: Primary adrenal lymphoma (PAL) is easily misdiagnosed as other adrenal masses, such as adrenocortical carcinoma and pheochromocytoma, but patients with PAL benefit little from surgery. The diagnostic method for PAL thus far is limited to adrenal biopsy. In our study, we aimed to develop a quick and efficient diagnostic method for PAL. METHODS AND RESULTS: At the same institution, 505 patients (between 2009 and 2019) and 171 patients (between 2019 and 2020) were separately included in the primary and validation studies. Univariate and multivariate analyses were conducted to evaluate clinical manifestations, laboratory findings, and radiological characteristics. Four determinants (age, bilateral masses, high-density lipoprotein cholesterol, and lactate dehydrogenase) were selected and further incorporated into a regression model to screen PAL. Accordingly, the nomogram was developed for clinical practice. In the primary study, the nomogram showed good discrimination, with an area under the receiver operating characteristic (ROC) curve (AUC) of 95.4% (95% CI, 90.6%–100.0%). Further validation study verified the efficacy of the nomogram, with an AUC of 99.0% (95% CI, 96.9%–100.00%) and 100.0% in all patients and patients with bilateral masses, respectively, and a sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV) of 66.67%/99.40%/66.67%/99.40%, 66.67%/100%/100%/92.86%, 50%/99.20%/50%/99.20%, and 100%/100%/100%/100%, in all patients, patients with bilateral adrenal masses, patients with nonfunctional adrenal masses, and patients with positive catecholamine results, respectively. The validation study also revealed a diagnostic specificity of 99.35% and 100% for patients with a unilateral adrenal mass and functional PCC, respectively. CONCLUSIONS: The presented nomogram is the first user-friendly diagnostic model for PAL that simplifies the complex diagnostic process into personalized numeric estimates. We deem that patients who score below 50 are less likely to have PAL. We suggest that clinicians should arrange adrenal biopsy and surgery for patients with nonfunctional tumors and overt catecholamine-secreting tumors, respectively, who receive a score of 50 points or higher to confirm the diagnosis as soon as possible. Frontiers Media S.A. 2021-04-02 /pmc/articles/PMC8050348/ /pubmed/33868171 http://dx.doi.org/10.3389/fendo.2021.636658 Text en Copyright © 2021 Yu, Xue, Zhou, Tian, Xiang, Chen and Ren https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Yu, Kai
Xue, Qingping
Zhou, Fangli
Tian, Haoming
Xiang, Qiao
Chen, Tao
Ren, Yan
A Novel Diagnostic Model for Primary Adrenal Lymphoma
title A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_full A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_fullStr A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_full_unstemmed A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_short A Novel Diagnostic Model for Primary Adrenal Lymphoma
title_sort novel diagnostic model for primary adrenal lymphoma
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050348/
https://www.ncbi.nlm.nih.gov/pubmed/33868171
http://dx.doi.org/10.3389/fendo.2021.636658
work_keys_str_mv AT yukai anoveldiagnosticmodelforprimaryadrenallymphoma
AT xueqingping anoveldiagnosticmodelforprimaryadrenallymphoma
AT zhoufangli anoveldiagnosticmodelforprimaryadrenallymphoma
AT tianhaoming anoveldiagnosticmodelforprimaryadrenallymphoma
AT xiangqiao anoveldiagnosticmodelforprimaryadrenallymphoma
AT chentao anoveldiagnosticmodelforprimaryadrenallymphoma
AT renyan anoveldiagnosticmodelforprimaryadrenallymphoma
AT yukai noveldiagnosticmodelforprimaryadrenallymphoma
AT xueqingping noveldiagnosticmodelforprimaryadrenallymphoma
AT zhoufangli noveldiagnosticmodelforprimaryadrenallymphoma
AT tianhaoming noveldiagnosticmodelforprimaryadrenallymphoma
AT xiangqiao noveldiagnosticmodelforprimaryadrenallymphoma
AT chentao noveldiagnosticmodelforprimaryadrenallymphoma
AT renyan noveldiagnosticmodelforprimaryadrenallymphoma